One major biotech investor just walked away from Viking Therapeutics. Here’s what the move may—and may not—mean for the company’s clinical-stage future.
A major biotech investor just walked away from MoonLake after a rough year for the stock. Here’s what that move signals—and what long-term investors should keep an eye on next.
One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks.
As the digital age continues its relentless march, a new contender has emerged for the title of the world's most valuable commodity: neural data. Far surpassing traditional resources like oil or even conventional personal data, information gleaned directly from the human nervous system is rapidly becoming the "black gold" of
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Centessa Pharmaceuticals revealed promising interim Phase 1 trial results for ORX750, demonstrating significant improvements in sleep latency for acutely sleep-deprived healthy volunteers. The company plans to advance ORX750 into Phase 2 studies targeting narcolepsy and idiopathic hypersomnia in Q4 2024.
